Caspofungin/TMP-SMX versus clindamycin/primaquine as salvage therapy for refractory non-HIV Pneumocystis pneumonia: a retrospective cohort study
Frontiers in Cellular and Infection Microbiology · 20.11.2026 · 16
DOI: 10.3389/fcimb.2026.1967637 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 20.11.2026. Verfasst von Xi Wang und 6 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Optimal salvage therapy for non-HIV-infected immunocompromised adults with progressive Pneumocystis jirovecii pneumonia (PJP) failing first-line trimethoprim–sulfamethoxazole (TMP-SMX) remains undefined. Caspofungin plus TMP-SMX has emerged as a potential salvage option through dual inhibition of β-1,3-D-glucan synthesis in cysts and folate synthesis in trophozoites. However, comparative data against clindamycin plus primaquine are lacking. Study design and methods This retrospective cohort included non-HIV-infected immunocompromised adults with proven/probable PJP who developed clinical failure after at least 5 days of TMP-SMX treatment (defined as absence of clinical improvement accompanied by respiratory deterioration requiring escalation of oxygen support) and received salvage therapy with either caspofungin plus TMP-SMX (caspofungin group) or clindamycin plus primaquine (C-P group). The primary outcome was 28-day all-cause mortality.
Results
Of 41 patients, 19 were in the caspofungin group and 22 in the C-P group. Baseline SOFA-2 scores and respiratory support at salvage initiation were comparable. The 28-day mortality rate was 47.4% (95% CI, 27.3–68.3%) in the caspofungin group versus 54.5% (95% CI, 34.7–73.1%) in the C-P group (P = 0.758). The 90-day mortality also did not differ significantly (47.4% vs. 59.1%; P = 0.538). After adjusting for invasive mechanical ventilation and bacterial coinfection in multivariable analysis, the salvage regimen was not an independent predictor of 28-day mortality (OR, 0.872; 95% CI, 0.202 - 3.475; P = 0.852). No adverse events were specifically attributed to caspofungin. In the C-P group, methemoglobinemia was detected on arterial blood gas analysis in 81.8% of patients (18/22); 10 patients had methemoglobin levels >10% and 5 required methylene blue administration and/or primaquine discontinuation.
Conclusion
In this small retrospective cohort, mortality did not differ significantly between the two salvage strategies. Methemoglobin elevation was frequent during clindamycin–primaquine treatment, whereas no caspofungin-attributed adverse events were recorded. Given the exploratory design, these findings should not be interpreted as evidence of therapeutic equivalence or a safety advantage for either regimen.
Zitieren
APA
Wang, X., Gao, X., Wang, S., Li, W., Yu, K., Yu, Q., & Ma, J. (2026). Caspofungin/TMP-SMX versus clindamycin/primaquine as salvage therapy for refractory non-HIV Pneumocystis pneumonia: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1967637
Vancouver
Wang X, Gao X, Wang S, Li W, Yu K, Yu Q, et al. Caspofungin/TMP-SMX versus clindamycin/primaquine as salvage therapy for refractory non-HIV Pneumocystis pneumonia: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1967637
BibTeX
@article{Wang2026,
author = {Wang, Xi and Gao, Xinran and Wang, Shixuan and Li, Weijian and Yu, Kunyao and Yu, Qing and Ma, Jing},
title = {Caspofungin/TMP-SMX versus clindamycin/primaquine as salvage therapy for refractory non-HIV Pneumocystis pneumonia: a retrospective cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1967637}
}
EUVIMED